Jan van de Winkel is President and Chief Executive Officer of Genmab, which he co-founded in February 1999. Genmab is a leading international biotechnology company focused on developing innovative antibody therapeutics for cancer.
Dr. van de Winkel has overseen the creation and development of a number of human antibodies for the treatment of cancer and other diseases.
Genmab has two approved and marketed drugs, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of several chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, NKT-cell lymphoma, myelodysplastic syndrome, amyloidosis and solid tumors. A subcutaneous formulation of ofatumumab is in Phase III development for relapsing multiple sclerosis. Genmab has a broad pre-clinical and clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.
Dr. van de Winkel has over 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 70 patents and patent applications. Dr. van de Winkel holds a professorship of Immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Biotech AG, member of the board of directors of LEO Pharma and Celdara Medical, the scientific advisory board of Thuja Capital Healthcare Fund and the advisory board of Capricorn Health-tech Fund.
MEET JAN VAN DE WINKEL AT #KFG2018
Jan van de Winkel will present a plenary talk in the morning programme:
“Genmab – Building an antibody innovation powerhouse”